This article is more than 5 years old. Information may no longer be current.

Positive topline results announced for phase 3 trial of Sun Pharma's Seciera for dry eye

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Seciera for the treatment of dry eye disease has met primary and key secondary endpoints in a phase 3 confirmatory clinical trial, according to a Sun Pharma press release.

The 12-week, multicenter, randomized, double-masked, vehicle-controlled trial included 744 dry eye patients who were treated with Seciera (cyclosporine A 0.09% ophthalmic solution) or its vehicle.

Seciera showed a statistically significant improvement in the primary endpoint of Schirmer’s score after 12 weeks of treatment (P < .0001). The efficacy at 12 weeks was earlier than other dry eye drugs, the release said. In addition, the study met several secondary endpoints.